ArticleHuman genetics2026
Mosaic variants in the LIM homeobox 1 (LHX1) gene contribute to Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome.
Article in Human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional Characterization of theGenes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mayer–Rokitansky–Küster–Hauser (MRKH) syndrome presents as the congenital absence of the uterus and vagina and affects approximately 1 in 4500 women. Affected individuals have normal breast development, primary amenorrhea, and a 46,XX karyotype. Müllerian aplasia may be isolated (type 1) or associated with renal, skeletal, cardiac, and auditory anomalies (type 2). The pathogenesis of MRKH largely remains unknown, but the LHX1 gene, which encodes a transcription factor, is an attractive candidate. LHX1 has been extensively studied in animals but less studied in humans. The Lhx1-null mouse model is embryonic lethal, but conditional knockout models found it important for urogenital system development. Although several possible deleterious variants have been reported in humans, LHX1 has not been established as a cause of MRKH in OMIM. In this study, we identified heterozygous intragenic LHX1 deletions by qPCR in 3/134 (2.2%) individuals with MRKH, which were confirmed by RT-PCR of lymphoblast RNA. This 166 bp frameshift deletion produces a premature stop codon (c.676_841del;p.V226Ifs*120) and is predicted to disrupt the DNA-binding domain essential for function. Mapping of the variant in genomic DNA revealed an 1864 bp deletion encompassing intron 3, exon 4, and intron 4, with allele frequencies of 3.4, 6.2, and 1%, respectively, in the three patients. Our findings provide supportive evidence that a low-level mosaic likely pathogenic variant in LHX1 could contribute to the pathogenesis of MRKH with or without nonreproductive anomalies.
Indexed as
Identifiers
41632294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.